BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28056186)

  • 1. Tampering with cancer chemoresistance by targeting the TGM2-IL6-autophagy regulatory network.
    Zhang H; McCarty N
    Autophagy; 2017 Mar; 13(3):627-628. PubMed ID: 28056186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.
    Zhang H; Chen Z; Miranda RN; Medeiros LJ; McCarty N
    Cancer Res; 2016 Nov; 76(21):6410-6423. PubMed ID: 27488529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
    Brown KD
    Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
    Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
    Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase-mediated chemoresistance in cancer cells.
    Verma A; Mehta K
    Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation.
    Altuntas S; Rossin F; Marsella C; D'Eletto M; Diaz-Hidalgo L; Farrace MG; Campanella M; Antonioli M; Fimia GM; Piacentini M
    Oncotarget; 2015 Dec; 6(42):44941-54. PubMed ID: 26702927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase (TG2) in cancer biology.
    Mangala LS; Mehta K
    Prog Exp Tumor Res; 2005; 38():125-38. PubMed ID: 15746533
    [No Abstract]   [Full Text] [Related]  

  • 8. Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancer.
    Zhang S; Yao HF; Li H; Su T; Jiang SH; Wang H; Zhang ZG; Dong FY; Yang Q; Yang XM
    Cell Oncol (Dordr); 2023 Oct; 46(5):1473-1492. PubMed ID: 37246171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
    Chen Z; Teo AE; McCarty N
    Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
    Oh K; Lee OY; Park Y; Seo MW; Lee DS
    BMC Cancer; 2016 Sep; 16(1):724. PubMed ID: 27609180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation.
    Yeo SY; Itahana Y; Guo AK; Han R; Iwamoto K; Nguyen HT; Bao Y; Kleiber K; Wu YJ; Bay BH; Voorhoeve M; Itahana K
    Elife; 2016 Mar; 5():e07101. PubMed ID: 26956429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.
    Akar U; Ozpolat B; Mehta K; Fok J; Kondo Y; Lopez-Berestein G
    Mol Cancer Res; 2007 Mar; 5(3):241-9. PubMed ID: 17374730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
    Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
    Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers.
    Cho SY; Oh Y; Jeong EM; Park S; Lee D; Wang X; Zeng Q; Qin H; Hu F; Gong H; Liu X; Zhang G; Na D; Lee J; Chae J; Suh YS; Kong SH; Lee HJ; Kim JI; Park H; Zhang C; Yang HK; Lee C
    Exp Mol Med; 2020 May; 52(5):854-864. PubMed ID: 32467608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
    Kumar S; Donti TR; Agnihotri N; Mehta K
    Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of transglutaminase 2 under different oxidative stress conditions.
    Caccamo D; Currò M; Ferlazzo N; Condello S; Ientile R
    Amino Acids; 2012 Feb; 42(2-3):1037-43. PubMed ID: 21805137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress management by autophagy: Implications for chemoresistance.
    Huang Z; Zhou L; Chen Z; Nice EC; Huang C
    Int J Cancer; 2016 Jul; 139(1):23-32. PubMed ID: 26757106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer.
    Mehta K; Kumar A; Kim HI
    Biochem Pharmacol; 2010 Dec; 80(12):1921-9. PubMed ID: 20599779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase 2 at the crossroads between cell death and survival.
    Piacentini M; D'Eletto M; Falasca L; Farrace MG; Rodolfo C
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():197-246. PubMed ID: 22220475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.